Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor Rocilinostat (ACY-1215) and Bortezomib, Demonstrates Synergistic Antitumor Activity in Preclinical Models of Lymphoma
| Autor: | Amengual, Jennifer E, Johannet, Paul M *, Jones, Simon S, O'Connor, Owen A. * |
|---|---|
| Zdroj: | In Blood 16 November 2012 120(21):1650-1650 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|